查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1138364

全球口乾藥物市場-2022-2029

Global Xerostomia Therapeutics Market - 2022-2029
出版日期: | 出版商: DataM Intelligence | 英文 200 Pages | 商品交期: 約2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

市場動態

口腔乾燥症治療市場的增長受到多種因素的推動，例如化療使用的增加、意識的提高以及口腔乾燥症和相關疾病的患病率上升。

口乾症和相關疾病的日益流行正在增加對口乾症治療的需求並推動市場增長。

口乾症和高血壓、帕金森病、乾燥綜合徵和糖尿病等相關疾病的發病率不斷上升，對市場的增長產生了積極影響。糖尿病是口乾的主要原因之一，當身體使用液體製造尿液時，其他東西的水就會減少，這發生在糖尿病中。因此，糖尿病會導致身體脫水和口乾舌燥。口乾會加劇糖尿病的副作用，提高血糖水平，並對您的身體造成嚴重破壞。特別是對於糖尿病患者來說，口乾會導致經常蛀牙。這意味著當身體試圖對抗感染時，血糖水平會上升。口乾也會導致睡眠不足和味覺改變（口中有金屬味或酸味）。

口乾是老年人的常見病。研究表明，乾燥綜合徵是大約 40% 的老年人口乾的根本原因。乾燥綜合徵是類風濕關節炎中第三常見的自身免疫性疾病。乾燥綜合徵的人群患病率為 0.2%，每年每 100,000 人中有 4 例的發病率。乾燥綜合徵在女性中的發病率是男性的 20 倍。乾燥綜合徵會攻擊製造眼淚和唾液的腺體，導致口乾和眼睛乾澀，並增加口乾症病例。

高成本、藥物的潛在副作用和嚴格的法規將成為全球口乾症藥物市場增長的不利因素。

現有的口乾症治療方法成本高、缺乏療效和不常見的副作用，限制了全球口乾症藥物市場的增長。此外，美國食品和藥物管理局 (FDA) 對藥物批准的嚴格規定可能會阻礙市場增長。例如，以商品名Ethyol 銷售的氨磷汀是唯一經美國FDA 驗證可防止輻射引起的口乾症的可用藥物。

行業分析。

《全球口腔乾燥症治療藥物市場報告》預計將根據波特五力、研發、流行病學、監管、定價和管道分析等各種行業因素對市場進行深入分析。 .

COVID-19 影響分析

由於在大流行期間實施了許多限制措施來限制 COVID-19 的傳播，全球市場受到了負面影響，擾亂了供需鏈並減少了口腔乾燥症治療的銷售。我是。此外，社會化法規使定期健康檢查變得困難，導致大多數口乾症患者未被發現，這對全球口乾症藥物市場產生了負面影響。

全球口腔乾燥症治療市場報告將提供對大約 40 多個市場數據表、45 多個數字和 200 多頁（大約）的訪問。

內容

  • 調查方法
  • 調查目的和範圍

第 2 章市場定義和概述

第 3 章執行摘要

第 4 章市場動態

  • 市場影響因素
    • 驅動程序
      • 口乾症和相關疾病的病例增加
      • 研發進展
      • 市場策略
    • 限制因素
      • 藥物的副作用
      • 嚴格的監管機構
    • 商機
    • 影響分析

第5章行業分析

  • 波特五力分析
  • 流行病學分析
  • 研發
  • 管道分析
  • 供應鏈分析
  • 監管分析

第 6 章 COVID-19 分析

  • COVID-19 的市場分析
    • COVID-19 之前的市場情景
    • COVID-19 的當前市場情景
    • COVID-19 後或未來情景
  • COVID-19 期間的價格動態
  • 供需範圍
  • 大流行期間與市場相關的政府舉措
  • 製造商的戰略舉措
  • 總結

第 7 章按類型

  • 非處方藥
  • 處方藥

第 8 章按產品類型

  • 唾液分泌興奮劑
  • 唾液替代品
  • 牙醫
  • 人工唾液
  • 唾液腺筆

第 9 章按銷售渠道

  • 醫院藥房
  • 零售藥房
  • 在線藥店

第 10 章按地區劃分

  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 意大利
    • 西班牙
    • 其他歐洲
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 澳大利亞
    • 其他亞太地區
  • 中東和非洲

第 11 章競爭格局

  • 主要發展和戰略
  • 公司份額分析
  • 產品基準

第 12 章公司簡介

  • 第一三共公司
    • 公司簡介
    • 產品組合和描述
    • 主要亮點
    • 財務摘要
  • GlaxoSmithKline
  • Church & Dwight Co., Inc.
  • Colgate-Palmolive Company
  • Acacia Pharma Group plc
  • Hikma Pharmaceuticals plc
  • Lupin Ltd.
  • Parnell Pharmaceuticals Inc.
  • Pendopharm, Virginia Head and Neck Therapeutics, Inc.
  • Pfizer Inc. and
  • Sun Pharmaceutical Industries Ltd

第13章 DataM

簡介目錄
Product Code: DMPH2168

Market Overview

Xerostomia Therapeutics Market size was valued at US$ YY million in 2021 and is estimated to reach US$ YY million by 2029, growing at a CAGR of 3.8% during the forecast period (2022-2029).

Xerostomia is defined as dry mouth resulting from reduced or absent saliva flow. Xerostomia is not a disease but is a symptom of toxicity from chemotherapy, head and neck radiotherapy, adverse effects of medications, autoimmune disease, or other conditions such as uncontrolled diabetes, infections, and hormonal changes. Xerostomia occurs commonly in those with Sjogren disease or who are receiving radiation therapy for head and neck cancer. Xerostomia is a common complaint among older adults, affecting approximately 20% of the elderly. Reduced salivary flow can cause difficulties in tasting, chewing, swallowing, and speaking; it can also increase the chance of developing dental decay, demineralizing teeth, tooth sensitivity, and oral infections.

Market Dynamics

The xerostomia therapeutics market growth is driven by several factors, such as an increase in chemotherapy, growing awareness and rising prevalence of xerostomia and associated diseases.

The growing prevalence of xerostomia and associated diseases has increased the demand for xerostomia therapeutics fueling the market growth.

The growing occurrence of xerostomia and related diseases such as hypertension, Parkinson's disorder, Sjogren's syndrome and diabetes positively impact market growth. Diabetes is one of the major causes that causes of dry mouth; there is less moisture for other things when the body is using fluids to make urine, which happens in diabetes. Diabetes hence leads to a dehydrated body and mouth that feels dry. Xerostomia can exacerbate the side effects of diabetes, increasing glucose levels and wreaking havoc on the body. Having xerostomia, especially as a diabetes patient, can lead to rampant tooth decay, which means blood sugar increases as the body tries to fight infection. A dry mouth can also lead to loss of sleep and an altered sense of taste, a condition that presents a metallic or sour taste in the mouth.

Xerostomia is a common symptom in the elderly population. Studies have suggested that the underlying cause of approximately 40% of xerostomia in the elderly is Sjogren's syndrome. Sjogren's syndrome is the third most common rheumatic autoimmune disorder. The population prevalence of Sjogren's syndrome is 0.2%, with an incidence of 4 cases per 100,000 per year. Sjogren's is 20 times more common in females than males. Sjogren's syndrome attacks the glands that make tears and saliva; this causes a dry mouth and dry eyes, increasing the cases of xerostomia.

The high cost, chances of drug side effects and stringent regulations will be the demoting reasons for the global xerostomia therapeutics market growth.

The High cost, ineffectiveness and common and uncommon side effects of available treatments for xerostomia are restraining the growth of the global xerostomia therapeutics market. In addition, stringent U.S. Food and Drug Administration (FDA) regulations for drug approval can hamper market growth. For instance, Amifostine-sold under the trade name Ethyol is the only drug available validated by the U.S FDA for protecting radiation-induced xerostomia.

Industry analysis.

The global xerostomia therapeutics market report will provide an in-depth analysis of the market based on various industry factors such as porter`s five forces, research and developments, epidemiology, regulatory, pricing, and pipeline analysis.

COVID-19 Impact Analysis

In the pandemic, the global market was negatively affected as many restrictions were imposed to limit the COVID-19 spread, which led to the disruption of the supply and demand chain, reducing the sales of the Xerostomia therapeutics. Furthermore, the socializing restriction made it difficult to get regular healthcare checkups, leaving most Xerostomia patients undetected, negatively impacting the global Xerostomia therapeutics market.

Segment Analysis

Salivary stimulants are presumed to be prevailing throughout the forecast period (2022-2029)

Salivary stimulants are expected to be the largest market shareholder over the period forecast (2022-2029). Topical salivary stimulant flow products include over-the-counter sugar-free gums, mints, and candies. Salivary stimulants include the sialagogues pilocarpine hydrochloride (Salagen®) and cevimeline hydrochloride (Evoxac®). Pilocarpine and cevimeline bind to muscarinic receptors, stimulating exocrine gland activity (such as salivary and sweat glands) and increasing smooth muscle tone in the gastrointestinal and urinary tracts. Common adverse effects include sweating, headache, GI discomfort, nausea, increased lacrimation, urinary frequency, and palpitations. Sialogogic drugs are substances designed to stimulate salivary secretion as they affect the systemic pathway. Using sugar-free chewing gum or tablet can increase salivary secretion and improve the sensation of dry mouth with gustatory and masticatory stimulation. These products include fluoride, chlorhexidine, calcium phosphate, and xylitol releasers. Salivary stimulants are highly popular as they are readily available and can be taken without adverse effects.

Geographical Analysis

The North American region is overshadowing the global xerostomia therapeutics market.

North America was dominating the xerostomia therapeutics market in 2021. It is estimated to hold the largest market size over the forecast period (2022-2029), owing to an increase in cancer and xerostomia-associated disorders such as Sjogren's disorder, a highly aware population, advanced healthcare infrastructure, favorable government initiatives and growth in research and development. As per the National Cancer Institute, in 2020, around 1,806,590 new cancer cases were diagnosed in the US, and 606,520 people died. These numbers increase yearly, along with the causes such as lifestyle changes, smoking, etc. The US is very advanced in healthcare, and the population is generally aware; this leads to growing chemotherapy treatment cases leading to xerostomia.

Similarly, other diseases associated with xerostomia, such as Parkinson's and Sjogren's syndrome, are also on the rise in the region; Sjogren's occurs in 0.1 to 1 percent of the population and is one of the most prevalent autoimmune diseases. Nine out of 10 patients are women. Initiatives launched by various organizations, such as the "5-year breakthrough goal" by Sjogren's Syndrome Foundation, focus on faster diagnosis and better treatment.

Competitive Landscape

Some of the major key players in the market are GlaxoSmithKline, Church & Dwight Co., Inc., Colgate-Palmolive Company, Acacia Pharma Group plc, Hikma Pharmaceuticals plc, Lupin Ltd., Parnell Pharmaceuticals Inc., Pendopharm, Virginia Head and Neck Therapeutics, Inc., Pfizer Inc. and Sun Pharmaceutical Industries Ltd. In the xerostomia therapeutics market, GlaxoSmithKline will dominate the market, owning to portfolio expansion, mergers, collaborations, and acquisitions. The key players are adopting various growth strategies such as mergers & acquisitions, partnerships, and collaborations and increasing research and development and high investment, contributing to the growth of the global xerostomia therapeutics market. For instance, on February 11, 2021, Virginia Head and Neck Therapeutics, Inc. introduced the Voutia device, which provides continuous relief from xerostomia.

Daiichi Sankyo Company

Overview

Daiichi Sankyo Company, Limited is a leading global pharmaceutical company and is the second-largest pharmaceutical company in Japan. As of March 2020, it has 15,348 employees. Daiichi Sankyo Company was founded in 2005 and is headquartered in Tokyo, Japan.

Product Portfolio

Daiichi Sankyo Company's xerostomia product portfolio has Evoxac.

The global xerostomia therapeutics market report would provide access to approximately 40+ market data tables, 45+ figures, and in the range of 200 (approximate) pages.

Table of Contents

Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Growing Cases Growing Prevalence of Xerostomia And Associated Diseases
      • 4.1.1.2. Research and Development
      • 4.1.1.3. Market Strategies
    • 4.1.2. Restraints
      • 4.1.2.1. Drug Side Effects
      • 4.1.2.2. Stringent Regulatory Bodies
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Epidemiological Analysis
  • 5.3. Research and Developments
  • 5.4. Pipeline Analysis
  • 5.5. Supply Chain Analysis
  • 5.6. Regulatory Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturer's Strategic Initiatives
  • 6.6. Conclusion

7. By Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type Segment
    • 7.1.2. Market Attractiveness Index, By Type Segment
  • 7.2. OTC
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, US$ Million, 2021-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 7.3. Prescription

8. By Product Type

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type Segment
    • 8.1.2. Market Attractiveness Index, By Product Type Segment
  • 8.2. Salivary Stimulants
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, US$ Million, 2021-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 8.3. Salivary Substitutes
  • 8.4. Dentifrices
  • 8.5. Artificial Saliva
  • 8.6. Salivary Pen

9. By Distribution Channels

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channels Segment
    • 9.1.2. Market Attractiveness Index, By Distribution Channels Segment
  • 9.2. Hospital Pharmacies
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis, US$ Million, 2021-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 9.3. Retail Pharmacies
  • 9.4. Online Pharmacies

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis, US$ Million, 2021-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 10.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 10.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. The U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 10.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 10.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. The U.K.
      • 10.3.6.3. France
      • 10.3.6.4. Italy
      • 10.3.6.5. Spain
      • 10.3.6.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan
      • 10.5.6.4. Australia
      • 10.5.6.5. Rest of Asia Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel

11. Competitive Landscape

  • 11.1. Key Developments and Strategies
  • 11.2. Company Share Analysis
  • 11.3. Product Benchmarking

12. Company Profiles

  • 12.1. Daiichi Sankyo Company
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Key Highlights
    • 12.1.4. Financial Overview
  • 12.2. GlaxoSmithKline
  • 12.3. Church & Dwight Co., Inc.
  • 12.4. Colgate-Palmolive Company
  • 12.5. Acacia Pharma Group plc
  • 12.6. Hikma Pharmaceuticals plc
  • 12.7. Lupin Ltd.
  • 12.8. Parnell Pharmaceuticals Inc.
  • 12.9. Pendopharm, Virginia Head and Neck Therapeutics, Inc.
  • 12.10. Pfizer Inc. and
  • 12.11. Sun Pharmaceutical Industries Ltd

LIST NOT EXHAUSTIVE

13. DataM

  • 13.1. Appendix
  • 13.2. About Us and Services
  • 13.3. Contact